[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356346-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356346-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","safety-and-preliminary-efficacy-results-of-ibi389-a-phase-1-dose-escalation-and-expansion-study","Safety and preliminary efficacy results of IBI389 - a phase 1 dose escalation and expansion study","","Phase I results evaluate safety and early efficacy of IBI389, an anti-Claudin18.2×CD3 bispecific antibody designed to engage T cells via binding to CD3 and Claudin18.2 and to form immune synapses. Eligible patients with advanced solid tumors progressed despite standard therapies. The study assessed treatment-related adverse events and cytokine release syndrome, with safety as the primary objective and RECIST v1.1 endpoints as secondary outcomes, including ORR and DCR.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/safety-and-preliminary-efficacy-results-of-ibi389-a-phase-1-dose-escalation-and-expansion-study/356346/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/safety-and-preliminary-efficacy-results-of-ibi389-a-phase-1-dose-escalation-and-expansion-study/356346.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is IBI389 and what is its intended mechanism of action?","Question",{"text":63,"@type":64},"IBI389 is an anti-Claudin18.2×CD3 bispecific antibody that engages T cells by binding CD3 and Claudin18.2, promoting immune synapse formation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was safety evaluated in this phase I study?",{"text":68,"@type":64},"Safety was assessed as the primary objective using treatment-related adverse events (TRAEs), dose-limiting toxicity (DLT), and cytokine release syndrome (CRS) related adverse events, including grades 1–2 and one grade 3 event.",{"name":70,"@type":61,"acceptedAnswer":71},"What preliminary efficacy outcomes were reported for Claudin18.2-positive GC/GEJC patients?",{"text":72,"@type":64},"In the subgroup expressing Claudin18.2 at levels of 2+ or 3+ (≥10%), ORR was 22.2% and DCR was 74.1%, with median PFS of 4.3 months and median OS of 10.3 months.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356346,1790330557,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":33,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Li etal. BMC Medicine (2026) 24:91  \n[https://doi.org/10.1186/s12916-025-04597-8](https://doi.org/10.1186/s12916-025-04597-8)  \nBMC Medicine  \n RESEARCH Open Access  \nSafety and preliminary efficacy results   of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumorsand gastric or gastro-esophageal tumors:  \na phase 1 dose escalation and expansion study  \nXiaoyu Li1†, Ruihong Dai2†, Qi Xu3, Zengqing Guo4, Changlu Hu5, Yuping Sun6, Zuoxing Niu7, Jihui Hao8, Mingjun Zhang9, Guanghai Dai10, Dong Hua11, Yueyin Pan12, Xin Wang13, Shuqing Wei14, Xiaobing Chen15, Qian Wu16, Yulong Zhang17, Hui Zhou18, Jieer Ying3*, Li Zheng1* and Feng Bi2*  \nAbstract  \nBackground Claudin18 .2 is a promising therapeutic target expressed in various solid tumors, particularly gastric cancer. IBI389 is a novel anti-Claudin18 .2 × CD3 bispecific antibody designed to engage T cells by binding CD3 and Claudin18 . 2, thereby induce immune synapse formation. Herein, we report preliminary results from a phase I study to evaluate safety and efficacy of IBI389 in patients with advanced solid tumors.  \nMethods Eligible patients with advanced solid tumors refractory to standard treatments were enrolled.  \nThe dose escalation of IBI389 monotherapy used intra-patient dose escalation with accelerated titration (0 . 003/0 . 01/0 . 03/0 . 1/0 . 3/1 µg/kg Q2W) and the classical 3 + 3 design (3/5/10/30/100/300/600 µg/kg Q3W) . Selected dose levels were expanded in patients with advanced gastric/gastroesophageal junction cancer (GC/GEJC) and pancreatic ductal adenocarcinoma. The primary objective was safety. Secondary objective was efficacy assessed by investigator per RECIST v1 .1 including objective response rate (ORR) and disease control rate (DCR) .  \nResults A total of 121 patients with solid tumors were enrolled, comprising 23 gastric cancer, 14 gastroesophageal junction cancer, 73 pancreatic adenocarcinoma, and 11 other gastrointestinal solid tumors. No dose-limiting toxicity (DLT) was observed during escalation, and the maximum tolerated dose was not reached. Treatment-related adverse events (TRAEs) occurred in 120 patients (99 . 2%), with the most common grade ≥ 3 TRAE being gamma-glutamyltransferase increased (21 . 5%) and lymphocytopenia (14 . 0%) and other grade ≥ 3 TRAEs were ≤ 5% . Cytokine release syndrome (CRS) related adverse events occurred in 72 patients (59 . 5%), all grades 1–2 except one grade 3 event. No  \n†Xiaoyu Li and Ruihong Dai are co-first author.  \n*Correspondence: Jieer Ying [jieerying@aliyun.com](jieerying@aliyun.com)[ ](jieerying@aliyun.com)Li Zheng [zhengli@wchscu.cn](zhengli@wchscu.cn)[ ](zhengli@wchscu.cn)Feng Bi[bifeng@scu.edu.cn](bifeng@scu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nLi etal. BMC Medicine (2026) 24:91 Page 2 of 16  \nneur","cbCaioZlCV7ewLcC","https://ap.wps.com/l/cbCaioZlCV7ewLcC","pdf",1290531,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n## Trial registration","[{\"question\":\"What is IBI389 and what is its intended mechanism of action?\",\"answer\":\"IBI389 is an anti-Claudin18.2×CD3 bispecific antibody that engages T cells by binding CD3 and Claudin18.2, promoting immune synapse formation.\"},{\"question\":\"How was safety evaluated in this phase I study?\",\"answer\":\"Safety was assessed as the primary objective using treatment-related adverse events (TRAEs), dose-limiting toxicity (DLT), and cytokine release syndrome (CRS) related adverse events, including grades 1–2 and one grade 3 event.\"},{\"question\":\"What preliminary efficacy outcomes were reported for Claudin18.2-positive GC/GEJC patients?\",\"answer\":\"In the subgroup expressing Claudin18.2 at levels of 2+ or 3+ (≥10%), ORR was 22.2% and DCR was 74.1%, with median PFS of 4.3 months and median OS of 10.3 months.\"}]","Safety and preliminary efficacy results of IBI389 - a phase 1 dose escalation and expansion study | PDF",1790124945,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/151199f3320da7b04c9c022ec2c2001b.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/566688eddb98c2f81777fc632df1fbb5.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3276a51d98a429951b2d0cfc617aa58e.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be2bfb5cb12494ece4760dd20b45b4a2.webp",980,1301]